1.Mosley JW., Rakela J. Founding viruses and transfusion medicine. Transfusion. 1999. 39:1041–4.
2.World Health Organization. Recommendations for production, control and regulation of human plasma for fractionation. WHO Technical Report Series 941. WHO expert committee on biological standardization. Genava: WHO;2007.
3.Horowitz B. Blood protein derivative viral safety: observations and analysis. Yale J Biol Med. 1990. 63:361–9.
4.Blümel J., Schmidt I., Effenberger W., Seitz H., Willkommen H., Brackmann HH, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2002. 42:1473–81.
Article
5.Wu CG., Mason B., Jong J., Erdman D., McKernan L., Oakley M, et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion. 2005. 45:1003–10.
Article
6.Chudy M., Budek I., Keller-Stanislawski B., McCaustland KA., Neidhold S., Robertson BH, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol. 1999. 57:91–9.
Article
7.Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf. (Update on Feb. 1996.
8.Webert KE., Cserti CM., Hannon J., Lin Y., Pavenski K., Pendergrast JM, et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev. 2008. 22:1–34.
Article
9.Yokoyama T., Murai K., Murozuka T., Wakisaka A., Tanifuji M., Fujii N, et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang. 2004. 86:225–9.
Article
10.Kleinman SH., Glynn SA., Lee TH., Tobler L., Montalvo L., Todd D, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007. 47:1756–64.
Article
11.Parsyan A., Candotti D. Human erythrovirus B19 and blood transfusion-an update. Transfus Med. 2007. 17:263–78.
12.Soucie JM., Robertson BH., Bell BP., McCaustland KA., Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998. 38:573–9.
Article
13.Lawlor E., Graham S., Davidson E., Yap PL., Cunningham C., Daly H, et al. Hepatitis A transmission by factor IX concentrates. Vox Sang. 1996. 71:126–8.
Article
14.U.S. FDA. Viral clearance processes for plasma derivatives. Guide to inspections of viral clearance process for plasma derivatives. http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074866.htm. (Update on Nov 2009).
15.Committee for Proprietary Medicinal Products. Note for guidance on plasma-derived medical products. http://www.emea.europa.eu/pdfs/human/bwp/026995en.pdf. (Update on Jan. 2001.
16.Furuya K., Murai K., Yokoyama T., Maeno H., Takeda Y., Murozuka T, et al. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process. Vox Sang. 2006. 91:119–25.
Article
17.Kasper CK, Costa e Silva M, editors. Registry of clotting factor concentrates. 6th ed.Quebec: World federation of hemophilia;2005. p. 1–9.
18.Japanese Red Cross Plasma Fractionation Center. Receipt inspection/virus inactivation and removal. http://www.pfc.jrc.or.jp/01/05.html. (Update on Sep. 2009.